Differential Conditioned Place Preference Responses to Endomorphin-1 and Endomorphin-2 Microinjected into the Posterior Nucleus Accumbens Shell and Ventral Tegmental Area in the Rat
An unbiased conditioned place preference (CPP) paradigm was used to evaluate the reward effects of endogenous μ-opioid receptor ligands endomorphin-1 (EM-1) and endomorphin-2 (EM-2) from the mesolimbic posterior nucleus accumbens (Acb) shell and the ventral tegmental area (VTA) in CD rats. EM-1 (1....
Saved in:
Published in | The Journal of pharmacology and experimental therapeutics Vol. 309; no. 2; pp. 816 - 824 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Pharmacology and Experimental Therapeutics
01.05.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | An unbiased conditioned place preference (CPP) paradigm was used to evaluate the reward effects of endogenous μ-opioid receptor
ligands endomorphin-1 (EM-1) and endomorphin-2 (EM-2) from the mesolimbic posterior nucleus accumbens (Acb) shell and the
ventral tegmental area (VTA) in CD rats. EM-1 (1.6-8.1 nmol) microinjected into posterior Acb shell produced CPP, whereas
EM-2 (8.7-17.5 nmol) given into the same Acb shell produced conditioned place aversion (CPA). EM-1 (1.6-16.3 nmol) microinjected
into the VTA produced CPP, whereas EM-2 (8.7 and 17.5 nmol) given into the same VTA site did not produce any effect, but at
a high dose (35 nmol) produced CPP. EM-1 (3.3 nmol) or EM-2 (17.5 nmol) microinjected into the nigrostriatal substantia nigra
was not significantly different from vehicle-injected groups. d -Phe-Cys-Tyr- d -Trp-Orn-Thr-Pen-Thr-NH 2 (CTOP) at 94.13 pmol or 3-methoxynaltrexone at 0.64 pmol microinjected into the posterior Acb shell blocked EM-1-induced
CPP and EM-2-induced CPA. At a higher dose, CTOP (941.3 pmol) and 3-methoxynaltrexone (6.4 pmol) produced CPA and CPP, respectively.
Coadministration with antiserum against dynorphin A(1-17) (Dyn) (10 μg) microinjected into the posterior Acb shell blocked
EM-2-induced CPA. However, it did not affect EM-1-induced CPP. It is concluded that EM-1 and EM-2 produce site-dependent CPP
and CPA, respectively, by stimulation of different subtypes of μ-opioid-receptors; stimulation of one subtype of μ-opioid-receptor
at the posterior Acb shell and VTA by EM-1 induces CPP, whereas stimulation of another subtype of μ-opioid receptor at the
posterior Acb shell, but not the VTA, by EM-2 induces the release of Dyn to produce CPA. |
---|---|
AbstractList | An unbiased conditioned place preference (CPP) paradigm was used to evaluate the reward effects of endogenous μ-opioid receptor
ligands endomorphin-1 (EM-1) and endomorphin-2 (EM-2) from the mesolimbic posterior nucleus accumbens (Acb) shell and the
ventral tegmental area (VTA) in CD rats. EM-1 (1.6-8.1 nmol) microinjected into posterior Acb shell produced CPP, whereas
EM-2 (8.7-17.5 nmol) given into the same Acb shell produced conditioned place aversion (CPA). EM-1 (1.6-16.3 nmol) microinjected
into the VTA produced CPP, whereas EM-2 (8.7 and 17.5 nmol) given into the same VTA site did not produce any effect, but at
a high dose (35 nmol) produced CPP. EM-1 (3.3 nmol) or EM-2 (17.5 nmol) microinjected into the nigrostriatal substantia nigra
was not significantly different from vehicle-injected groups. d -Phe-Cys-Tyr- d -Trp-Orn-Thr-Pen-Thr-NH 2 (CTOP) at 94.13 pmol or 3-methoxynaltrexone at 0.64 pmol microinjected into the posterior Acb shell blocked EM-1-induced
CPP and EM-2-induced CPA. At a higher dose, CTOP (941.3 pmol) and 3-methoxynaltrexone (6.4 pmol) produced CPA and CPP, respectively.
Coadministration with antiserum against dynorphin A(1-17) (Dyn) (10 μg) microinjected into the posterior Acb shell blocked
EM-2-induced CPA. However, it did not affect EM-1-induced CPP. It is concluded that EM-1 and EM-2 produce site-dependent CPP
and CPA, respectively, by stimulation of different subtypes of μ-opioid-receptors; stimulation of one subtype of μ-opioid-receptor
at the posterior Acb shell and VTA by EM-1 induces CPP, whereas stimulation of another subtype of μ-opioid receptor at the
posterior Acb shell, but not the VTA, by EM-2 induces the release of Dyn to produce CPA. An unbiased conditioned place preference (CPP) paradigm was used to evaluate the reward effects of endogenous mu-opioid receptor ligands endomorphin-1 (EM-1) and endomorphin-2 (EM-2) from the mesolimbic posterior nucleus accumbens (Acb) shell and the ventral tegmental area (VTA) in CD rats. EM-1 (1.6-8.1 nmol) microinjected into posterior Acb shell produced CPP, whereas EM-2 (8.7-17.5 nmol) given into the same Acb shell produced conditioned place aversion (CPA). EM-1 (1.6-16.3 nmol) microinjected into the VTA produced CPP, whereas EM-2 (8.7 and 17.5 nmol) given into the same VTA site did not produce any effect, but at a high dose (35 nmol) produced CPP. EM-1 (3.3 nmol) or EM-2 (17.5 nmol) microinjected into the nigrostriatal substantia nigra was not significantly different from vehicle-injected groups. D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2) (CTOP) at 94.13 pmol or 3-methoxynaltrexone at 0.64 pmol microinjected into the posterior Acb shell blocked EM-1-induced CPP and EM-2-induced CPA. At a higher dose, CTOP (941.3 pmol) and 3-methoxynaltrexone (6.4 pmol) produced CPA and CPP, respectively. Coadministration with antiserum against dynorphin A(1-17) (Dyn) (10 microg) microinjected into the posterior Acb shell blocked EM-2-induced CPA. However, it did not affect EM-1-induced CPP. It is concluded that EM-1 and EM-2 produce site-dependent CPP and CPA, respectively, by stimulation of different subtypes of mu-opioid-receptors; stimulation of one subtype of mu-opioid-receptor at the posterior Acb shell and VTA by EM-1 induces CPP, whereas stimulation of another subtype of mu-opioid receptor at the posterior Acb shell, but not the VTA, by EM-2 induces the release of Dyn to produce CPA. |
Author | Randy J. Leitermann Kuei-chun Hung Andrew D. Clithero Hsiang-en Wu Maia Terashvili Emma T. Schwasinger Leon F. Tseng |
Author_xml | – sequence: 1 givenname: Maia surname: Terashvili fullname: Terashvili, Maia organization: Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA – sequence: 2 givenname: Hsiang-en surname: Wu fullname: Wu, Hsiang-en – sequence: 3 givenname: Randy J surname: Leitermann fullname: Leitermann, Randy J – sequence: 4 givenname: Kuei-chun surname: Hung fullname: Hung, Kuei-chun – sequence: 5 givenname: Andrew D surname: Clithero fullname: Clithero, Andrew D – sequence: 6 givenname: Emma T surname: Schwasinger fullname: Schwasinger, Emma T – sequence: 7 givenname: Leon F surname: Tseng fullname: Tseng, Leon F |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/14755004$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkU1v3CAQhlGVqtmkPfdWcerNGzDgj-NqmzaV0jZK014RxsOalQ0uYFX5Yf1_IbsrRb3AMMw888J7gc6cd4DQe0rWlJb8aj9DWlPC1kS0ZVO_QisqSlqQnDpDK0LKsmCiEufoIsY9IZTzir1B55TXQhDCV-jfJ2sMBHDJqhFvvettsnlGj-9GpQHfBThc5_Ae4uxdhIiTx9eu95MP82BdQbFy_X-ZEn-zOnjr9qBTZlmXW9KQcT4mCNYH_H3RIywRb7Repg5cxD8HGMcD6neWE7KcB9hNOczRJoDKlAPjXqW36LVRY4R3p_0S_fp8_bC9KW5_fPm63dwWmpU8FW3Nm7bUhoneVFSbDozpedfUTV01hgDkletGVZx3qiXMKNo1rDOgScd7EOwSfTxy5-D_LBCTnGzUWaZy4Jcoa9oIUTGWC6-OhfnVMeY_k3OwkwqPkhL57JR8diofmDw6lTs-nNBLN0H_Un-y5mX2YHfDXxtAzoMKk9J-9LtHyUgrS9nQij0BhR-i9Q |
CitedBy_id | crossref_primary_10_1007_s00213_010_1946_0 crossref_primary_10_1111_j_1530_0277_2010_01310_x crossref_primary_10_1016_j_neuroscience_2012_05_033 crossref_primary_10_1111_bph_16287 crossref_primary_10_1016_j_peptides_2005_02_006 crossref_primary_10_1016_j_neuropharm_2016_03_017 crossref_primary_10_1021_acs_jmedchem_1c01631 crossref_primary_10_1111_j_1369_1600_2007_00070_x crossref_primary_10_1016_j_ejphar_2008_03_020 crossref_primary_10_1016_j_peptides_2008_04_012 crossref_primary_10_1016_j_neubiorev_2005_06_001 crossref_primary_10_1007_s00213_012_2753_6 crossref_primary_10_1152_physrev_00005_2009 crossref_primary_10_1016_j_neuroscience_2014_09_025 crossref_primary_10_1016_j_pbb_2013_11_004 crossref_primary_10_1016_j_peptides_2008_05_014 crossref_primary_10_1016_j_nbd_2008_09_018 crossref_primary_10_1016_j_bbr_2016_07_017 crossref_primary_10_1016_j_ejphar_2007_01_083 crossref_primary_10_1016_j_bbr_2013_03_046 crossref_primary_10_1016_j_physbeh_2009_02_004 crossref_primary_10_1016_j_jecm_2013_08_002 crossref_primary_10_1523_JNEUROSCI_4569_08_2008 crossref_primary_10_1016_j_neulet_2004_03_093 crossref_primary_10_1016_j_brainres_2013_04_004 crossref_primary_10_1016_j_peptides_2005_06_010 crossref_primary_10_1124_jpet_108_136739 |
Cites_doi | 10.1016/S0306-4522(01)00151-8 10.1016/S0006-8993(96)01119-5 10.1016/0014-2999(91)90774-K 10.1038/386499a0 10.1007/978-1-4613-8817-3_2 10.1016/0304-3940(90)90823-R 10.1016/0006-8993(83)90913-7 10.1007/BF02255469 10.1523/JNEUROSCI.09-10-03538.1989 10.1016/0166-2236(88)90093-8 10.1037/0735-7044.111.6.1324 10.1007/BF02532373 10.1254/jjp.89.224 10.1016/S0014-2999(01)01238-9 10.1124/jpet.102.038810 10.1615/CritRevNeurobiol.v12.i4.10 10.1146/annurev.ps.40.020189.001203 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-# 10.1046/j.1460-9568.2000.00936.x 10.1523/JNEUROSCI.22-16-07225.2002 10.1038/sj.bjp.0702330 10.1523/JNEUROSCI.22-09-03312.2002 10.1016/0014-2999(95)00185-N 10.1016/S0306-4522(99)00298-5 10.1016/S0014-2999(02)01984-2 10.1016/S0014-2999(98)00395-1 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1124/jpet.103.059287 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0103 |
EndPage | 824 |
ExternalDocumentID | 10_1124_jpet_103_059287 14755004 309_2_816 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NIDA NIH HHS grantid: DA12588 |
GroupedDBID | - 08R 0R 2WC 3O- 4.4 53G 55 5GY 5RE 8RP AALRV ABFLS ABIVO ABOCM ABSGY ABZEH ACDCL ACGFS ACNCT ADACO ADBIT ADCOW ADKFC AENEX AETEA AFFNX AIKQT ALMA_UNASSIGNED_HOLDINGS CS3 DIK DL DU5 E3Z EBS EJD F5P FH7 GJ GX1 H13 HZ INIJC KQ8 L7B LSO O0- O9- OHT OK1 P2P R.V R0Z RHF RHI RPT W2D WH7 WOQ X X7M ZGI ZXP --- -~X .55 .GJ 0R~ 18M 5VS 8WZ A6W AAJMC AAYOK ABCQX ABJNI ABSQV ACGFO ADBBV ADIYS AERNN AFHIN AFOSN AGFXO AI. BAWUL BTFSW CGR CUY CVF ECM EIF F9R HZ~ MJL MVM NPM TR2 UQL VH1 W8F YBU YHG YQT AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c324t-974892cf35df61cfbeffd4b878768f0ee68f4c8a644ba903fa1b83bfec0b4de53 |
ISSN | 0022-3565 |
IngestDate | Sat Aug 17 00:04:41 EDT 2024 Thu Sep 26 17:48:17 EDT 2024 Sat Sep 28 07:40:05 EDT 2024 Tue Jan 05 21:16:48 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c324t-974892cf35df61cfbeffd4b878768f0ee68f4c8a644ba903fa1b83bfec0b4de53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 14755004 |
PQID | 71855633 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_71855633 crossref_primary_10_1124_jpet_103_059287 pubmed_primary_14755004 highwire_pharmacology_309_2_816 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 20040501 2004-May 2004-05-00 |
PublicationDateYYYYMMDD | 2004-05-01 |
PublicationDate_xml | – month: 05 year: 2004 text: 20040501 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of pharmacology and experimental therapeutics |
PublicationTitleAlternate | J Pharmacol Exp Ther |
PublicationYear | 2004 |
Publisher | American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: American Society for Pharmacology and Experimental Therapeutics |
References | 2019081412051117000_309.2.816.5 2019081412051117000_309.2.816.24 2019081412051117000_309.2.816.23 2019081412051117000_309.2.816.4 2019081412051117000_309.2.816.25 2019081412051117000_309.2.816.9 2019081412051117000_309.2.816.42 2019081412051117000_309.2.816.41 2019081412051117000_309.2.816.7 2019081412051117000_309.2.816.22 (2019081412051117000_309.2.816.36) 1993; 226 2019081412051117000_309.2.816.21 (2019081412051117000_309.2.816.6) 1998; 286 (2019081412051117000_309.2.816.20) 1996; 21 (2019081412051117000_309.2.816.17) 1984; 3 (2019081412051117000_309.2.816.33) 1992; 89 (2019081412051117000_309.2.816.43) 2002; 22 (2019081412051117000_309.2.816.1) 1993; 264 2019081412051117000_309.2.816.28 2019081412051117000_309.2.816.27 2019081412051117000_309.2.816.35 2019081412051117000_309.2.816.34 (2019081412051117000_309.2.816.2) 1989; 6 2019081412051117000_309.2.816.15 (2019081412051117000_309.2.816.37) 2000; 292 2019081412051117000_309.2.816.31 (2019081412051117000_309.2.816.10) 2003; 33 (2019081412051117000_309.2.816.26) 2001; 298 2019081412051117000_309.2.816.30 (2019081412051117000_309.2.816.8) 1989; 9 2019081412051117000_309.2.816.11 2019081412051117000_309.2.816.32 (2019081412051117000_309.2.816.13) 1990; 253 (2019081412051117000_309.2.816.3) 2002; 22 (2019081412051117000_309.2.816.29) 2000; 88 2019081412051117000_309.2.816.39 (2019081412051117000_309.2.816.12) 1992; 450 2019081412051117000_309.2.816.16 2019081412051117000_309.2.816.38 (2019081412051117000_309.2.816.14) 1987; 241 2019081412051117000_309.2.816.19 (2019081412051117000_309.2.816.40) 2001; 299 2019081412051117000_309.2.816.18 |
References_xml | – ident: 2019081412051117000_309.2.816.24 doi: 10.1016/S0306-4522(01)00151-8 – ident: 2019081412051117000_309.2.816.35 doi: 10.1016/S0006-8993(96)01119-5 – ident: 2019081412051117000_309.2.816.34 doi: 10.1016/0014-2999(91)90774-K – ident: 2019081412051117000_309.2.816.42 doi: 10.1038/386499a0 – volume: 89 start-page: 2040 year: 1992 ident: 2019081412051117000_309.2.816.33 publication-title: Proc Natl Acad Sci USA – ident: 2019081412051117000_309.2.816.38 doi: 10.1007/978-1-4613-8817-3_2 – ident: 2019081412051117000_309.2.816.5 doi: 10.1016/0304-3940(90)90823-R – volume: 3 start-page: 617 year: 1984 ident: 2019081412051117000_309.2.816.17 publication-title: Neuroscience – volume: 264 start-page: 489 year: 1993 ident: 2019081412051117000_309.2.816.1 publication-title: J Pharmacol Exp Ther – ident: 2019081412051117000_309.2.816.7 doi: 10.1016/0006-8993(83)90913-7 – ident: 2019081412051117000_309.2.816.21 doi: 10.1007/BF02255469 – volume: 9 start-page: 3538 year: 1989 ident: 2019081412051117000_309.2.816.8 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.09-10-03538.1989 – ident: 2019081412051117000_309.2.816.15 doi: 10.1016/0166-2236(88)90093-8 – ident: 2019081412051117000_309.2.816.27 doi: 10.1037/0735-7044.111.6.1324 – volume: 33 start-page: 890 year: 2003 ident: 2019081412051117000_309.2.816.10 publication-title: Soc Neurosci Abstr – volume: 21 start-page: 1315 year: 1996 ident: 2019081412051117000_309.2.816.20 publication-title: Neurochem Res doi: 10.1007/BF02532373 – ident: 2019081412051117000_309.2.816.25 doi: 10.1254/jjp.89.224 – ident: 2019081412051117000_309.2.816.30 doi: 10.1016/S0014-2999(01)01238-9 – ident: 2019081412051117000_309.2.816.41 doi: 10.1124/jpet.102.038810 – ident: 2019081412051117000_309.2.816.32 doi: 10.1615/CritRevNeurobiol.v12.i4.10 – volume: 226 start-page: 1430 year: 1993 ident: 2019081412051117000_309.2.816.36 publication-title: J Pharmacol Exp Ther – ident: 2019081412051117000_309.2.816.39 doi: 10.1146/annurev.ps.40.020189.001203 – ident: 2019081412051117000_309.2.816.16 doi: 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-# – ident: 2019081412051117000_309.2.816.4 – volume: 450 start-page: 455 year: 1992 ident: 2019081412051117000_309.2.816.12 publication-title: J Pharmacol – volume: 298 start-page: 592 year: 2001 ident: 2019081412051117000_309.2.816.26 publication-title: J Pharmacol Exp Ther – ident: 2019081412051117000_309.2.816.19 doi: 10.1046/j.1460-9568.2000.00936.x – volume: 22 start-page: 7225 year: 2002 ident: 2019081412051117000_309.2.816.43 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-16-07225.2002 – ident: 2019081412051117000_309.2.816.23 doi: 10.1038/sj.bjp.0702330 – volume: 22 start-page: 3312 year: 2002 ident: 2019081412051117000_309.2.816.3 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-09-03312.2002 – ident: 2019081412051117000_309.2.816.31 doi: 10.1016/0014-2999(95)00185-N – volume: 292 start-page: 576 year: 2000 ident: 2019081412051117000_309.2.816.37 publication-title: J Pharmacol Exp Ther – ident: 2019081412051117000_309.2.816.18 doi: 10.1016/S0306-4522(99)00298-5 – volume: 286 start-page: 1007 year: 1998 ident: 2019081412051117000_309.2.816.6 publication-title: J Pharmacol Exp Ther – ident: 2019081412051117000_309.2.816.9 – ident: 2019081412051117000_309.2.816.11 doi: 10.1016/S0014-2999(02)01984-2 – volume: 6 start-page: 121 year: 1989 ident: 2019081412051117000_309.2.816.2 publication-title: Synapse – ident: 2019081412051117000_309.2.816.22 doi: 10.1016/S0014-2999(98)00395-1 – volume: 88 start-page: 1 year: 2000 ident: 2019081412051117000_309.2.816.29 publication-title: Brain Res – volume: 299 start-page: 1120 year: 2001 ident: 2019081412051117000_309.2.816.40 publication-title: J Pharmacol Exp Ther – volume: 253 start-page: 858 year: 1990 ident: 2019081412051117000_309.2.816.13 publication-title: J Pharmacol Exp Ther – volume: 241 start-page: 328 year: 1987 ident: 2019081412051117000_309.2.816.14 publication-title: J Pharmacol Exp Ther – ident: 2019081412051117000_309.2.816.28 |
SSID | ssj0014463 |
Score | 1.9571397 |
Snippet | An unbiased conditioned place preference (CPP) paradigm was used to evaluate the reward effects of endogenous μ-opioid receptor
ligands endomorphin-1 (EM-1)... An unbiased conditioned place preference (CPP) paradigm was used to evaluate the reward effects of endogenous mu-opioid receptor ligands endomorphin-1 (EM-1)... |
SourceID | proquest crossref pubmed highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 816 |
SubjectTerms | Animals Conditioning (Psychology) - drug effects Dynorphins - immunology Dynorphins - pharmacology Male Microinjections Naltrexone - analogs & derivatives Naltrexone - pharmacology Nucleus Accumbens - drug effects Nucleus Accumbens - physiology Oligopeptides - pharmacology Rats Receptors, Opioid, kappa - metabolism Receptors, Opioid, mu - metabolism Serum - metabolism Somatostatin - analogs & derivatives Somatostatin - pharmacology Space Perception - drug effects Substantia Nigra - drug effects Substantia Nigra - physiology Ventral Tegmental Area - drug effects Ventral Tegmental Area - physiology |
Title | Differential Conditioned Place Preference Responses to Endomorphin-1 and Endomorphin-2 Microinjected into the Posterior Nucleus Accumbens Shell and Ventral Tegmental Area in the Rat |
URI | http://jpet.aspetjournals.org/content/309/2/816.abstract https://www.ncbi.nlm.nih.gov/pubmed/14755004 https://search.proquest.com/docview/71855633 |
Volume | 309 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe28cIDiG86vvyAJqQuJbWdNHmcYGgaYiqjQ3uLYsfZ8kAytcmk8X_x_3Fnp4kzmDR4iSqrvSS9n3139t3vCHnLwGoJkTJPqEx7gvupJ7mOPDVLwzyTmc-VSZA9Cg9OxOFpcLqxec_JWmpqOVE__1pX8j9ahTHQK1bJ_oNmO6EwAJ9Bv3AFDcP1Vjr-2HY3qQuzBYCnz0g8lGErIpiv866HCO7SYyqs5XPYL7PqRwV_cFF6U3N64I4wTKVfVkWJOzQaqZla9xT7-sJbVcvxEZIgNytsNYENRcrV-BvmkxpR3-128Xihz9q-AXtLrMa06ZTH6eAsoC9MMy7xRc-jbWmhBv0HnFKxLhBYwNDq_LKwRd5f0qK3Mo2xqlgjeuZpJ_GoMMbIuu3HcJOr8eGkB3e79DW68NR5Uw42RUSfgjgoUrBtKCa6XdsZ7pz43F38uR87KGfOUh5NQ9crsJXefxocJtDgQISD9AUTcFZZ60AMqL2vmdwuEdKEYEwkKCABAYkVsEnusFkcYIrq56_9qRiE7rxjv4eXa6mqQMD7a08w9LLWzNc3R1HGm1o8IPdbndM9i-mHZEOXj8jO3Or_apcuHF3v0h06d5DxmPxygU8d4FMDfNoDn3bAp3VFB8CnoPvBCKMD4FMEPgXQ0Q74tAU-7YBPDfCNqBb4tAM-ReCDFCMDgP-EnHzaX3w48Nr-I56CMKP2YmRmYirnQZaHU5VLneeZkBHYuDDKfa3hKlSUQkgh09jneTqVEZe5Vr4UmQ74U7JVwss_J1TMeBzCD3wZZEKFECTEMuBZpMDG6pSJEXm31ldyYWlmkhuwMSJv1vpM3GmZAJQTlgBs4RtrNSdgLPAEMC111awScESREJCPyDOr_f5mYhYEMJG2b_8gL8jdfuq9JFv1stGvwEOv5WsD298W_e_E |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+Conditioned+Place+Preference+Responses+to+Endomorphin-1+and+Endomorphin-2+Microinjected+into+the+Posterior+Nucleus+Accumbens+Shell+and+Ventral+Tegmental+Area+in+the+Rat&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Terashvili%2C+Maia&rft.au=Wu%2C+Hsiang-en&rft.au=Leitermann%2C+Randy+J.&rft.au=Hung%2C+Kuei-chun&rft.date=2004-05-01&rft.issn=0022-3565&rft.eissn=1521-0103&rft.volume=309&rft.issue=2&rft.spage=816&rft.epage=824&rft_id=info:doi/10.1124%2Fjpet.103.059287&rft.externalDBID=n%2Fa&rft.externalDocID=10_1124_jpet_103_059287 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon |